These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A; HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419 [TBL] [Abstract][Full Text] [Related]
25. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407 [TBL] [Abstract][Full Text] [Related]
26. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167 [TBL] [Abstract][Full Text] [Related]
28. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Palacios R; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S; J Antimicrob Chemother; 2017 Jan; 72(1):246-253. PubMed ID: 27629070 [TBL] [Abstract][Full Text] [Related]
29. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Dejesus E; Mills A; Bhatti L; Conner C; Storfer S Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631 [TBL] [Abstract][Full Text] [Related]
30. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524 [TBL] [Abstract][Full Text] [Related]
31. Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. Avihingsanon A; Kerr SJ; Punyawudho B; van der Lugt J; Gorowara M; Ananworanich J; Lange JM; Cooper DA; Phanuphak P; Burger DM; Ruxrungtham K AIDS Res Hum Retroviruses; 2013 Dec; 29(12):1541-6. PubMed ID: 24088045 [TBL] [Abstract][Full Text] [Related]
32. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D; PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641 [TBL] [Abstract][Full Text] [Related]
33. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. Smith DE; Jeganathan S; Ray J HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461 [TBL] [Abstract][Full Text] [Related]
35. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058 [TBL] [Abstract][Full Text] [Related]
36. Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring? Metsu D; Seraissol P; Delobel P; Cinq-Frais C; Cuzin L; Izopet J; Chatelut E; Gandia P Fundam Clin Pharmacol; 2017 Apr; 31(2):245-253. PubMed ID: 27664801 [TBL] [Abstract][Full Text] [Related]
37. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S; Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881 [TBL] [Abstract][Full Text] [Related]
38. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Ward D; Zhao HH; Ross LL; Shaefer MS; HIV Clin Trials; 2012; 13(5):233-44. PubMed ID: 23134624 [TBL] [Abstract][Full Text] [Related]
39. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794 [TBL] [Abstract][Full Text] [Related]